医学
德诺苏马布
前列腺癌
中止
乳腺癌
不利影响
骨质疏松症
肿瘤科
随机对照试验
内科学
雄激素剥夺疗法
骨重建
泌尿科
外科
癌症
作者
Antonio Galvano,Dalila Scaturro,Giuseppe Badalamenti,Lorena Incorvaia,Sérgio Rizzo,Luisa Castellana,Stefania Cusenza,Sofia Cutaia,Daniele Santini,Fiorella Guadagni,Mario Roselli,Stefania Gori,M Latteri,Viviana Bazan,Letizia Mauro Giulia
标识
DOI:10.1016/j.jbo.2019.100252
摘要
Hormonal therapies for receptor positive-breast and prostate cancer patients have shown clinical efficacy but also several side effects including osteoporosis, loss of bone mass and increased fracture risk. Denosumab represents an anti RANKL (receptor activator of nuclear factor-kB ligand) monoclonal anti-body acting as inhibitor of osteoclasts formation, function, and survival, then increasing bone mass. Herein, we performed a systematic review and meta-analysis of randomized controlled trials (RCTs) to evaluate the role of Denosumab in saving bone health in prostate and breast cancer patients receiving respectively androgen deprivation therapy and adjuvant endocrine therapy. Moreover, selected patients have to be treated with Denosumab at the dose of 60 mg every six month or placebo. Outcomes studied included the bone mass density (BMD) increase at 24 and 36 months, BMD loss, reduction of fractures risk (in particular vertebral) at 24 and 36 months and safety (overall, serious adverse events – SAEs and discontinuation rate). Our results showed a reduction of the BMD loss up to 36 months both at the lumbar and femoral level and a BMD increase both at 24 and 36 months. It was also found a reduction in the number of new vertebral and femoral fractures at 24 and 36 months. Finally, our pooled analysis showed that Denosumab did not affect both the SAEs and therapy discontinuation risk. In conclusion, Denosumab administration can be considered effective and safe in the prevention and management of the above mentioned adverse events related to hormonal therapies designed for breast and prostate tumors.
科研通智能强力驱动
Strongly Powered by AbleSci AI